CN1817898A - Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound - Google Patents
Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound Download PDFInfo
- Publication number
- CN1817898A CN1817898A CN 200610024750 CN200610024750A CN1817898A CN 1817898 A CN1817898 A CN 1817898A CN 200610024750 CN200610024750 CN 200610024750 CN 200610024750 A CN200610024750 A CN 200610024750A CN 1817898 A CN1817898 A CN 1817898A
- Authority
- CN
- China
- Prior art keywords
- glaucogenin
- glycosyl
- pyrans
- saponin
- scheelite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 74
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 63
- 150000007949 saponins Chemical class 0.000 title claims abstract description 45
- -1 saponin compound Chemical class 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 230000003110 anti-inflammatory effect Effects 0.000 title description 5
- 235000017709 saponins Nutrition 0.000 claims abstract description 72
- 229930182589 Cynanoside Natural products 0.000 claims abstract description 17
- 229930193724 Atratoglaucoside Natural products 0.000 claims abstract description 13
- 229930002600 steroidal saponin Natural products 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims abstract description 7
- 208000005577 Gastroenteritis Diseases 0.000 claims abstract description 5
- 150000004880 oxines Chemical class 0.000 claims description 33
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims description 28
- 229930188483 glaucogenin Natural products 0.000 claims description 23
- ZCEYOMXMDDYIQP-WGKOQXAXSA-N glaucogenin-C Natural products C[C@]12CC[C@H](O)CC1=CC[C@H]3[C@@H]2CCC4=CO[C@@]5(C)OC[C@@H](OC3=O)[C@@H]45 ZCEYOMXMDDYIQP-WGKOQXAXSA-N 0.000 claims description 22
- ZCEYOMXMDDYIQP-ZYQXTWTMSA-N glaucogenin c Chemical compound O([C@@]1(OC=C(CC[C@@H]23)[C@@H]11)C)CC1OC(=O)[C@@H]2CC=C1[C@]3(C)CC[C@H](O)C1 ZCEYOMXMDDYIQP-ZYQXTWTMSA-N 0.000 claims description 18
- PNOYMYGRNNZTRO-OVMCULIESA-N glaucoside h Chemical compound O([C@@H]1[C@H](OC)C[C@@H](O[C@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](C)O[C@H](O[C@H]2[C@@H](C[C@]3(C)[C@@H]4[C@@H](C(O[C@@H]5CO[C@]6(C)OC=C([C@H]56)CC4)=O)CC=C3C2)O)C[C@H]1OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PNOYMYGRNNZTRO-OVMCULIESA-N 0.000 claims description 17
- 229930182478 glucoside Natural products 0.000 claims description 17
- 150000008131 glucosides Chemical class 0.000 claims description 17
- PNOYMYGRNNZTRO-UHFFFAOYSA-N komaroside D Natural products COC1CC(OC2C(CC3(C)C4C(C(OC5COC6(C)OC=C(C56)CC4)=O)CC=C3C2)O)OC(C)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC)C1OC1OC(CO)C(O)C(O)C1O PNOYMYGRNNZTRO-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- BRAQGYOYQRQKSH-UHFFFAOYSA-N amplexicoside B Natural products O1C(C)C(O)C(OC)CC1OC1C(C)OC(OC2C(CC(OC2C)OC2C(CC3(C)C4C(C(OC5COC6(C)OC=C(C56)CC4)=O)CC=C3C2)O)OC)CC1O BRAQGYOYQRQKSH-UHFFFAOYSA-N 0.000 claims description 14
- CDKBQXOPJCUYPU-UHFFFAOYSA-N cynaversicoside-D Natural products COC1CC(OC2C(C)OC(CC2OC)OC3C(C)OC(OC4CCC5(C)C6CCC7=COC8(C)OCC(OC(=O)C6C(O)C=C5C4)C78)C(O)C3OC)OC(C)C1O CDKBQXOPJCUYPU-UHFFFAOYSA-N 0.000 claims description 14
- WVGGFOSYFLHAEP-UHFFFAOYSA-N cynaversicoside-C Natural products COC1C(O)C(C)OC(OC2CCC3(C)C4CCC5=COC6(C)OCC(OC(=O)C4C(O)C=C3C2)C56)C1O WVGGFOSYFLHAEP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000038016 acute inflammation Diseases 0.000 claims description 10
- 230000006022 acute inflammation Effects 0.000 claims description 10
- BGLPWKQUOIXBNP-CTNBYYEDSA-N glaucogenin-A Natural products CO[C@H]1[C@H](O)[C@@H](C)O[C@H](O[C@@H]2CC3=CC[C@@H]4[C@H](CCC5=CO[C@@]6(C)OC[C@@H](OC4=O)[C@@H]56)[C@@]3(C)C[C@H]2O)[C@@H]1O BGLPWKQUOIXBNP-CTNBYYEDSA-N 0.000 claims description 10
- 208000037976 chronic inflammation Diseases 0.000 claims description 9
- 230000006020 chronic inflammation Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 241000107739 Vincetoxicum versicolor Species 0.000 claims description 7
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000001297 phlebitis Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 4
- 206010001093 acute tonsillitis Diseases 0.000 abstract description 3
- 201000007100 Pharyngitis Diseases 0.000 abstract 2
- 229930192824 albinoside Natural products 0.000 abstract 2
- 240000005125 Myrtus communis Species 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000016150 acute pharyngitis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 229950010050 oleandrin Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 125
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000004587 chromatography analysis Methods 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 241000107360 Vincetoxicum glaucescens Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000006837 decompression Effects 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 238000002481 ethanol extraction Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- 238000010828 elution Methods 0.000 description 9
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 9
- 238000004611 spectroscopical analysis Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 241000208327 Apocynaceae Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 208000012873 acute gastroenteritis Diseases 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- FMBUMRDTMFABLR-UHFFFAOYSA-N Atratoglaucoside A Natural products O1C(C)C(O)C(OC)CC1OC1C(OC)C(O)C(OC2CC3=CCC4C(=O)OC5COC6(C)OC=C(C56)CCC4C3(C)CC2)OC1C FMBUMRDTMFABLR-UHFFFAOYSA-N 0.000 description 1
- 241000587240 Cynanchum Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000028204 Vincetoxicum atratum Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- GZPAIOJUUWWJCN-UHFFFAOYSA-N chekiangensoside B Natural products COC1CC(OC2C(CC3(C)C4C(C(OC5COC6(C)OC=C(C56)CC4)=O)CC=C3C2)O)OC(C)C1OC(OC1C)CC(OC)C1OC(OC1C)CC(OC)C1OC1OC(CO)C(O)C(O)C1O GZPAIOJUUWWJCN-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属医药技术领域，具体为一种从中药白薇中提取得到的白薇总皂苷和白薇皂苷化合物及其在抗炎药物中的应用。该白薇皂苷化合物包括9种碳－21甾体皂苷，具体为：蔓生白薇苷A、蔓生白薇苷B、蔓生白薇苷C、蔓生白薇苷D、白前苷元C－3－O－β－D－黄花夹竹桃糖苷、白前苷C、白前苷H、atratoglaucosides A、cynanosides I，白薇总皂苷为含有这9种化合物中任意几种且总重量含量大于50％的混合物。经动物实验证明，这些化合物对各种炎症有显著的抑制作用，因此，可以制备抗炎症药物，用以治疗慢性咽喉炎、慢性肠胃炎、急性扁桃腺炎、上呼吸道感染、气管炎等急慢性炎症。The invention belongs to the technical field of medicine, and specifically relates to total saponins and a saponin compound of Baiwei extracted from the traditional Chinese medicine Baiwei and its application in anti-inflammatory drugs. The herbasaponin compound includes 9 kinds of carbon-21 steroidal saponins, specifically: rapamin A, rapamin B, rapamin C, rapamin D, rapagenin C-3- O-β-D-Oleandrin, albinoside C, albinoside H, atratoglaucosides A, cynanosides I, and total saponins of myrtle myrtle include any of these nine compounds and the total weight content is greater than 50%. mixture. Animal experiments have proved that these compounds have significant inhibitory effects on various inflammations. Therefore, anti-inflammatory drugs can be prepared to treat acute and chronic pharyngitis, chronic gastroenteritis, acute tonsillitis, upper respiratory tract infection, and bronchitis. inflammation.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the compound that a class has anti-inflammatory activity, radix cynanchi atrati saponin compound that especially extraction separation obtains from the Chinese medicine radix cynanchi atrati and scheelite total saponin(e, and in prevention with treat application in the various acute or chronic inflammation medicines.
Background technology
Radix cynanchi atrati is the root of the upright radix cynanchi atrati of asclepiadaceae (Asclepiadaceae) Cynanchum plant (Cynanchum atratumBunge.), Cynanchum versicolor Bunge (Cynanchum versicolor Bunge.), radix cynanchi atrati has the effect that clearing heat and cooling blood, inducing diuresis for treating stranguria syndrome, detoxifcation are treated sore in the theory of traditional Chinese medical science, is used for that temperature is evil hinders diseases such as battalion's heating, fever due to yin deficiency, hectic fever due to yin labor heat, postpartum fever due to deficiency of blood, heat pouring, blood pouring, swollen ulcer drug.Aqueous extract and alcohol extract to radix cynanchi atrati carried out some pharmacological researches in recent years, the extract that studies show that radix cynanchi atrati have bring down a fever, effect such as antimicrobial antiphlogistic and analgesia,
So far, still find no total saponins of radix cynanchi atrati and the bibliographical information that monomer saponin is made medicine thereof, the contriver confirms through great deal of experimental, scheelite total saponin(e and monomer saponin thereof have anti-inflammatory action, can prevent and treat various acute or chronic inflammations, and made medicament, finished the present invention.
Summary of the invention
The object of the present invention is to provide extraction obtains from the Chinese medicinal materials radix cynanchi atrati radix cynanchi atrati saponin compound and scheelite total saponin(e, and propose its application in anti-inflammatory drug.
The present invention's extraction separation from radix cynanchi atrati obtains having 9 kinds of carbon-21 steroidal saponin(es of anti-inflammatory activity, be specially: Cynanversicoside A, Cynanversicoside B, Cynaversicoside C, Cynaversicoside D, glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, glaucoside C, Glaucoside H, atratoglaucosides A, cynanosides I, and obtain comprising in 9 kinds of carbon-21 steroidal saponin(es several arbitrarily and the mixture of saponin compound total content (weight) 〉=50% is the scheelite total saponin(e.
Detect by analysis, 9 kinds of carbon-21 steroidal saponin(es among the present invention are 9 kinds of glucosides that a kind of and different quantities, the dissimilar sugar by 3 kinds of steroid sapogenins shown in following 3 chemical structures forms, and wherein R is a sugar chain:
glaucogenin A glaucogenin C glaucogenin D
Cynanversicoside A: aglycon is Glaucogenin C (glaucogenin C), and R is the lucky pyrans of β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl.
Cynanversicoside B: aglycon is Glaucogenin C (glaucogenin C), and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl.
Cynaversicoside C: aglycon is Glaucogenin D (Cynanchum glaucescens aglycon D), and R is β-D-Semen Thevetiae pyrans glycosyl.
Cynaversicoside D: aglycon is Glaucogenin D (Cynanchum glaucescens aglycon D), and R is the lucky pyrans of β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl.
Glaucogenin C-3-O-β-D-Semen Thevetiae glucosides: aglycon is Glaucogenin C (glaucogenin C), and R is β-D-Semen Thevetiae pyrans glycosyl.
Glaucoside C: aglycon is Glaucogenin A (Cynanchum glaucescens aglycon A), and R is the lucky pyrans of α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyrans glycosyl.
Glaucoside H: aglycon is Glaucogenin A (Cynanchum glaucescens aglycon A), and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyrans glycosyl.
Atratoglaucosides A: aglycon is Glaueogenin C (glaucogenin C), and R is the lucky pyrans of α-L-enlightening glycosyl-(1 → 4)-β-D-Folium seu Cortex Nerii pyrans glycosyl.
Cynanosides I: aglycon is Glaucogenin A (Cynanchum glaucescens aglycon A), and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl.
The present invention further proposes scheelite total saponin(e and radix cynanchi atrati saponin compound or is that the composition of primary activity composition is in prevention with treat the purposes of various acute or chronic inflammations and related diseases thereof with it, acute or chronic inflammation comprises upper respiratory tract infection, tonsillitis, pharyngolaryngitis, gastro-enteritis, pneumonia, trachitis, inflammation such as phlebitis.
Scheelite total saponin(e and radix cynanchi atrati saponin compound can become pharmaceutical composition with pharmaceutically acceptable vehicle group, make various preparations, comprising: tablet, granule, capsule, oral liquid, dripping pill, mixture, syrup, tincture, injection etc.Route of administration is oral, and through skin, snuffing is gone into, rectum, parenteral, vein or muscle etc.
Chemical part
Carbon-21 steroidal saponin(e provided by the invention and the mixture scheelite total saponin(e that includes any kind of carbon-21 steroidal saponin(e, their preparation method is, the radix cynanchi atrati medicinal material with ethanol etc. as extracting solvent, concentrating the medicinal extract that obtains separates through macroporous resin column chromatography, collect ethanol eluate, concentrate and obtain the scheelite total saponin(e.Again through silica gel column chromatography, detect the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, concentrate, separate and purifying through the RP-18 post again, get Cynanversicoside A, Cynanversicoside B, Cynaversicoside C, Cynaversicoside D, glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, glaucoside C, Glaucoside H, atratoglaucosides A, cynanosides I.
By spectral analysis techniques such as acid hydrolysis and UV spectrum, infrared spectra, high resolution fast atom bombardment MS, proton nmr spectra, carbon-13 nmr spectra, the relevant spectrum of heteronuclear volume, the relevant spectrums of heteronuclear multikey, the chemical structure of 9 kinds of carbon-21 steroidal saponin(es is illustrated, and is respectively: the lucky pyrans of Glaucogenin C (glaucogenin C)-3-O-(1 → 4)-β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyranoside; The lucky pyrans of Glaucogenin C (glaucogenin C)-3-O-(1 → 4)-β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyranoside; Glaucogenin D (Cynanchum glaucescens aglycon D)-3-O-(1 → 4)-β-D-Semen Thevetiae pyranoside; The lucky pyrans of Glaucogenin D (Cynanchum glaucescens aglycon D)-3-O-(1 → 4)-β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyranoside; Glaucogenin C (glaucogenin C)-3-O-β-D-Semen Thevetiae pyranoside; The lucky pyrans of GlaucogeninA (Cynanchum glaucescens aglycon A)-3-O-(1 → 4)-α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyranoside; The lucky pyrans of Glaucogenin A (Cynanchum glaucescens aglycon A)-3-O-(1 → 4)-β-D-glucopyanosyl base-(1 → 4)-α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyranoside; The lucky pyrans of Glaucogenin C (glaucogenin C)-3-O-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Folium seu Cortex Nerii pyranoside; The lucky pyrans of Glaucogenin A (Cynanchum glaucescens aglycon A)-3-O-(1 → 4)-β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Apocynum cannabinum pyranoside.
Physiologically active
The present invention has carried out the evaluation experimental of anti-inflammatory activity to radix cynanchi atrati total saponins and 9 compounds.
(1) mice ear model
1 laboratory animal
Swiss kind mouse, male, body weight 20-24g.
2. experimental model and testing method
Get 320 of mouse, be divided into 32 groups at random, press the dosage gastric infusion 3d shown in the table 3,1h after the last administration, dimethylbenzene with 0.05ml causes inflammation with mouse left side ear, the punch tool that with diameter is 7mm is the overlapping punching of ears, and the disk of laying is gone up weighing at torsion(type)balance (sensitivity be ten thousand/), represents its swelling degree with the weight difference of mouse ear two disks.
3 statistical study:
All experimental result is all represented with mean ± standard error.Respectively organize data and the blank significant difference of organizing with student t-check, P＜0.05, expression difference has the significance meaning.
4 test-results:
Table 1. scheelite total saponin(e and saponin compound are to the influence of mice ear test
| Group | Dosage (mg/kg) | n | Ear swelling (mg) | Inhibiting rate (%) |
| Blank | - | 10 | 18.59±1.38 | - |
| Hydrocortisone | 20 | 10 | 10.71±1.11 * | 42.4 |
| Cynanversicoside A | 10 | 10 | 13.49±1.96 | 27.4 |
| 20 40 | 10 10 | 13.24±0.80 * 10.11±2.21 ** | 28.7 45.6 | |
| Cynanversicoside B | 10 20 40 | 10 10 10 | 16.15±5.10 12.22±1.05 * 13.25±5.76 * | 13.1 34.3 28.7 |
| Cynaversicoside C | 10 20 40 | 10 10 10 | 13.21±1.96 * 10.01±0.81 ** 3.15±2.22 *** | 28.9 46.2 69.4 |
| Cynaversicoside D | 10 20 40 | 10 10 10 | 12.15±4.00 * 10.00±1.04 ** 9.90±0.98 ** | 34.6 46.2 46.7 |
| Glaucogenin C-3-O-β-D-Semen Thevetiae glucosides | 10 20 40 | 10 10 10 | 10.49±1.09 ** 10.00±0.53 ** 2.17±0.21 *** | 43.6 46.2 88.3 |
| Glaucoside C | 10 20 40 | 10 10 10 | 13.15±1.10 * 12.22±1.05 * 10.25±1.12 ** | 29.3 34.3 44.9 |
| Glaucoside H | 10 20 40 | 10 10 10 | 13.50±1.06 13.49±0.80 10.01±1.21 ** | 27.4 27.4 46.2 |
| Atratoglaucosides A | 10 20 40 | 10 10 10 | 16.15±5.10 10.21±1.05 ** 10.25±0.71 ** | 13.1 45.1 44.9 |
| Cynanosides I | 10 20 40 | 10 10 10 | 10.49±1.91 ** 10.14±0.74 ** 2.17±0.23 *** | 43.6 45.7 88.3 |
| The scheelite total saponin(e | 20 50 100 | 10 10 10 | 10.79±0.70 * 10.02±1.75 ** 3.26±0.46 *** | 42.0 46.2 82.5 |
Compare with the blank group,
*P＜0.05,
*P＜0.01,
* *P＜0.001
The result shows, positive control drug hydrocortisone, 9 radix cynanchi atrati saponin(es and scheelite total saponin(e have significant inhibitory effect to the inflammation that the mice ear model causes, wherein the action effect of Cynaversicoside C, glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, Cynanosides I and scheelite total saponin(e is stronger.
(2) rat carrageenan foot swelling model
1 laboratory animal
The SD rat, male and female dual-purpose, body weight 180-220g.
2. experimental model and testing method
Get 320 of rats, be divided into 32 groups at random, press the dosage gastric infusion 4d shown in the table 4, before the last administration, measure and cause scorching preceding volume; 30min after the last administration, the sufficient subcutaneous injection 1% carrageenin 0.1ml that wastes time causes inflammation in rat right hind leg.Respectively at cause scorching back 2,4,6h measures the following volume of right ankle joint.
3 statistical study:
All experimental result is all represented with mean ± standard error.Respectively organize data and the blank significant difference of organizing with student t-check, P＜0.05, expression difference has the significance meaning.
4 test-results:
Table 2. scheelite total saponin(e and saponin compound are to the influence of rat carrageenan foot swelling test
| Group | Dosage (mg/kg) | n | Paw swelling (ml) | ||
| 2h | 4h | 6h | |||
| Blank | - | 10 | 1.22±0.08 | 1.01±0.12 | 0.94±0.16 |
| Dexamethasone | 300 | 10 | 0.30±0.12 ** | 0.36±0.10 ** | 0.26±0.09 ** |
| Cynanversicoside A | 10 20 40 | 10 10 10 | 1.22±0.11 1.07±0.62 * 0.76±0.6 ** | 0.91±0.12 0.84±0.26 * 0.30±0.60 ** | 0.99±0.24 0.84±0.37 0.50±0.16 * |
| Cynanversicoside B | 10 20 40 | 10 10 10 | 1.32±0.12 1.08±0.10 * 0.81±0.08 ** | 1.21±0.31 1.07±0.64 0.86±0.60 * | 1.01±0.21 1.01±0.34 0.86±0.60 |
| Cynaversicoside C | 10 20 40 | 10 10 10 | 1.08±0.12 * 1.06±0.09 * 0.52±0.21 ** | 0.92±0.21 0.83±0.65 * 0.29±0.56 ** | 0.82±0.20 0.53±0.44 * 0.25±0.26 ** |
| Cynaversicoside D | 10 20 40 | 10 10 10 | 1.05±0.11 * 1.06±0.19 * 0.42±0.07 ** | 1.11±0.21 0.84±0.42 * 0.31±0.44 ** | 0.97±0.23 0.54±0.24 * 0.56±0.23 * |
| Glaucogenin C-3-O-β-D-Semen Thevetiae glucosides | 10 20 40 | 10 10 10 | 1.04±0.21 * 1.04±0.19 * 0.32±0.12 ** | 0.79±0.91 * 0.35±0.63 ** 0.10±0.06 *** | 0.79±0.91 0.32±0.61 ** 0.09±0.11 *** |
| Glaucoside C | 10 20 40 | 10 10 10 | 1.20±0.10 1.06±0.29 * 0.82±0.11 ** | 1.42±0.51 1.07±0.52 0.84±0.43 * | 1.12±0.47 0.96±0.33 0.52±0.13 * |
| Glaucoside H | 10 20 40 | 10 10 10 | 1.32±0.21 * 1.19±0.17 1.05±0.17 * | 1.22±0.11 1.07±0.62 * 0.76±0.60 ** | 1.24±0.25 0.98±0.26 0.76±0.27 |
| Atratoglaucoside A | 10 20 40 | 10 10 10 | 1.05±0.13 * 1.04±0.09 * 0.53±0.07 ** | 1.22±0.11 1.07±0.62 0.76±0.56 ** | 0.92±0.14 1.07±0.62 0.33±0.63 ** |
| Cynanosides I | 10 20 40 | 10 10 10 | 1.04±0.08 * 0.50±0.17 ** 0.32±0.07 ** | 0.83±0.44 * 0.77±0.35 * 0.36±0.17 ** | 0.81±0.47 0.53±0.20 * 0.32±0.17 ** |
| The scheelite total saponin(e | 20 50 100 | 10 10 10 | 1.07±0.11 * 0.61±0.11 ** 0.40±0.17 ** | 1.02±0.15 0.87±0.42 * 0.35±0.13 ** | 0.99±0.35 0.60±0.44 * 0.29±0.23 ** |
Compare with the blank group,
*P＜0.05,
*P＜0.01,
* *P＜0.001
The result shows, positive control drug dexamethasone, 9 radix cynanchi atrati saponin(es and scheelite total saponin(e have significant inhibitory effect to the caused inflammation of rat carrageenan foot swelling model, and the action effect of glaucogenin C-3-O-β-D-Semen Thevetiae glucosides is stronger.
(3) mouse peritoneal capillary permeability test
1 laboratory animal
NH is a mouse, male and female dual-purpose, body weight 18-22g.
2. experimental model and testing method
Get 320 of rats, be divided into 32 groups at random, press the dosage gastric infusion 1h shown in the table 5, tail vein injection 2% AZO-blue normal saline solution 0.1ml/10g body weight, abdominal injection 0.8% acetic acid normal saline solution 0.20ml/ only takes off cervical vertebra and puts to death mouse behind the 20min immediately, divides with 5ml physiological saline and washs the abdominal cavity for several times, 3000 rev/mins, centrifugal 15min; Getting supernatant liquor uses microplate reader in its optical density(OD) of 570nm colorimetric estimation (OD) value.
3 statistical study:
All experimental result is all represented with mean ± standard error.Respectively organize data and the blank significant difference of organizing with student t-check, P＜0.05, expression difference has the significance meaning.
4 test-results:
Table 3. scheelite total saponin(e and saponin compound are to the influence of mouse peritoneal capillary permeability test
| Group | Dosage (mg/kg) | n | Abdominal cavity capillary penetration liquid OD value (λ=570nm) |
| Blank | - | 10 | 0.77±0.33 |
| Dexamethasone | 1.5 | 10 | 0.37±0.22 * |
| Cynanversicoside A | 10 20 40 | 10 10 10 | 0.55±0.18 0.66±0.36 0.44±0.29 * |
| Cynanversicoside B | 10 20 40 | 10 10 10 | 0.66±0.24 0.47±0.11 * 0.41±0.27 * |
| Cynaversicoside C | 10 20 40 | 10 10 10 | 0.75±0.13 0.45±0.21 * 0.37±0.12 * |
| Cynaversicoside D | 10 20 40 | 10 10 10 | 0.65±0.09 0.43±0.12 * 0.41±0.28 * |
| Glaucogenin C-3-O-β-D-Semen Thevetiae glucosides | 10 20 40 | 10 10 10 | 0.69±0.09 0.37±0.20 * 0.33±0.02 * |
| Glaucoside C | 10 20 40 | 10 10 10 | 0.65±0.14 0.46±0.20 * 0.43±0.10 * |
| Glaucoside H | 10 20 | 10 10 | 0.78±0.11 0.66±0.22 |
| 40 | 10 | 0.42±0.12 * | |
| Atratoglaucosides A | 10 20 40 | 10 10 10 | 0.66±0.17 0.47±0.25 * 0.41±0.18 * |
| Cynanosides I | 10 20 40 | 10 10 10 | 0.65±0.13 0.37±0.15 * 0.31±0.12 * |
| The scheelite total saponin(e | 20 50 100 | 10 10 10 | 0.65±0.23 0.40±0.19 * 0.36±0.17 * |
Compare with the blank group,
*P＜0.05,
*P＜0.01,
* *P＜0.001
The result shows, positive control drug dexamethasone, 9 radix cynanchi atrati saponin(es and the scheelite total saponin(e inflammation that test causes to the mouse peritoneal capillary permeability have significant inhibitory effect.
Embodiment
Embodiment 1:
Preparation scheelite total saponin(e
After radix cynanchi atrati dry root 10kg pulverizes, with 10 times of amount 90% alcohol refluxs 3 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, with macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, till being eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part, i.e. scheelite total saponin(e sample.Wherein, radix cynanchi atrati saponin compound content is more than 60%.
The scheelite total saponin(e, pale brown toner end, Lieberman-Burchard and Keller-Killiani reaction all are positive, and show to be all the steroidal compounds that contains the 2-desoxy sugar.
Embodiment 2:
Preparation Cynanchum versicolor Bunge A
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out the purification on normal-phase silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with its A V flow point that is through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying get Cynanversicoside A.
Cynanversicoside A (cynanversicoside A), white amorphous powder, mp120-124 ℃, [α]
D 28:-59.28 ° (c=0.521, MeOH), molecular formula: C
42H
64O
15Through spectroscopic data analysis and physicochemical character measure with bibliographical information (QiuSheng-Xiang, et al.Plata.Med., 1991,57, Cynanversicoside A 454.-456) is in full accord.
Embodiment 3:
The preparation Cynanversicoside B
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol alcohol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein A IV flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Cynanversicoside B.
Cynanversicoside B (cynavesicoside B), white amorphous powder, mp160-164 ℃, [α]
D 28:-60.98 ° (c=0.50, MeOH), molecular formula: C
48H
72O
20Through spectroscopic data analysis and physicochemical character measure with bibliographical information (QiuSheng-Xiang, et al.Plata.Med., 1991,57, Cynanversicoside B 454.-456) is in full accord.
Embodiment 4:
The preparation Cynaversicoside C
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein B IV flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Cynaversicoside C.
Cynaversicoside C (cynanversicoside C), white amorphous powder, mp124-128 ℃, [α]
D 28:+49.8 ° (c=0.562, MeOH), molecular formula: C
28H
40O
14Through spectroscopic data analysis and physicochemical character measure with bibliographical information (QiuSheng-Xiang, et al.Phytochemistry, 1989,28 (11), Cynaversicoside C 3175-3178) is in full accord.
Embodiment 5:
The preparation Cynaversicoside D
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein B III flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Cynaversicoside D.
Cynaversicoside D (cynanversicoside D), white amorphous powder, mp:150-152 ℃, [α]
D 28:-8.7 ° (c=0.52, EtOH), molecular formula: C
42H
64O
16Through spectroscopic data analysis and physicochemical character measure with bibliographical information (QiuSheng-Xiang, et al.Phytochemistry, 1989,28 (11), Cynaversicoside D 3175-3178) is in full accord.
Embodiment 6:
Preparation glaucogenin C-3-O-β-D-Semen Thevetiae glucosides
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein B II flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain glaucogenin C-3-O-β-D-Semen Thevetiae glucosides.
Glaucogenin C-β-D-Semen Thevetiae glucosides (glaucogenin C-β-D-thevetopyranoside), white amorphous powder, mp:187-190 ℃, [α]
D 28:+27.4 ° of (c=1.03, CHCl
3), molecular formula: C
28H
40O
9Through spectroscopic data analysis and physicochemical character measure with bibliographical information (Takashi Nakagawa, et al.Chem.Pharm.Bull., 1983,31, glaucogenin C 870-877)-3-O-β-D-Semen Thevetiae glucosides is in full accord.
Embodiment 7:
The preparation glaucoside C
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein A I flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain glaucoside C.
Glaucoside C (glaucoside C), white amorphous powder, mp:127-133 ℃, [α]
D 28:-14.6 ° of (c=0.91, CHCl
3), molecular formula: C
41H
62O
15Through spectroscopic data analysis and physicochemical character measure with bibliographical information (Takashi Nakagawa, et al.Tetrahedron, 1983,39 (4), glaucoside C 607-612) is in full accord.
Embodiment 8:
The preparation Glaucoside H
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein A II flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Glaucoside H.
Glaucoside H (glaucoside H), white amorphous powder, mp:150-154 ℃, [α]
D 28:-29.6 ° of (c=0.98, CHCl
3), molecular formula: C
47H
72O
20Through spectroscopic data analysis and physicochemical character measure with bibliographical information (Zhang Zhuang-Xin, et al.Chem.Pharm.Bull.1985,33 (10), Glaucoside H 4188-4192) is in full accord.
Embodiment 9:
Preparation Atratoglaucosides A
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein A III flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Atratoglaucosides A.
Atratoglaucosides A, white amorphous powder, mp:120-127 ℃, [α]
D:-21 ° of (c=0.16, CHCl
3), molecular formula: C
35H
52O
12Through spectroscopic data analysis and physicochemical character measure with bibliographical information (Day Shiow-Hwa, et al.J.Nal.Prod.2001,64, Atratoglaucosides A 608-611) is in full accord.
Embodiment 10:
Preparation Cynanosides I
After radix cynanchi atrati dry root 10kg pulverizes, measure 90% alcohol refluxs 3 times with 10 times, each 2 hours, united extraction liquid, decompression and solvent recovery, get ethanol extraction, macroporous resin HP-20 post on this extract, it is colourless to be eluted to elutriant with distilled water and 30%EtOH respectively, be eluted to sulfuric acid ethanol saponin(e colour developing feminine gender with 90%EtOH again till, reclaim the 90%EtOH elutriant to doing, get 90%EtOH wash-out part.The 90%EtOH wash-out is partly carried out silica gel column chromatography, carry out gradient elution with chloroform-methanol, check the chromatography flow point with thin-layer chromatography, flow point with identical single spot merges, and concentrates, and gets flow point 1,2,3,4,5,3 and 4 parts are wherein carried out the purification on normal-phase silica gel column chromatography more respectively, chloroform-methanol in varing proportions carries out wash-out, flow point 3 A I-VII flow point, flow point 4 B I-V flow point, with wherein B I flow point through repeatedly RP-C18 chromatography (MeOH:H
2O) separation, purifying obtain Cynanosides I.
Cynanosides I, white amorphous powder, [α]
D:-10.5 ° of (c=1.10, CHCl
3), molecular formula: C
48H
74O
20Through spectroscopic data analysis and physicochemical character measure with bibliographical information (Bai Hong, et al.Tetrahedron.2005,61, Cynanoside I 5797-5811) is in full accord.
Embodiment 11:
Get the scheelite total saponin(e 100g among the embodiment 1, disperse, add right amount of auxiliary materials, mixing with an amount of water for injection, make particle, drying is pressed into 1000, every 0.1g, sugar coating promptly get scheelite total saponin(e sheet, and other project should meet under Pharmacopoeia of People's Republic of China version tablet in 2005 item.This tablet is used for prevention and treatment chronic inflammatory diseases such as chronic pharyngolaryngitis, chronic enterogastritis etc., has good effect.
Embodiment 12:
Get scheelite total saponin(e 100g, make 5% scheelite total saponin(e solution with 75% dissolve with ethanol, use activated carbon decolorizing, filter the concentrating under reduced pressure drying, add the injection water and make the aqueous solution that every ml contains 20mg scheelite total saponin(e, filter to clear and bright, aseptic subpackaged in the control antibiotic glass bottle every bottle of 5ml with millipore filtration (φ 0.20 μ m), put lyophilize in the freeze drier, promptly.This powder injection is used for the treatment of acute inflammation such as acute tonsillitis, upper respiratory tract infection, acute gastroenteritis etc., has good result.
Embodiment 13:
Get scheelite total saponin(e 1kg, 0.5 ton of medical starch, with 80% ethanol wet granulation, whole grain, dress 2# capsule, every 0.2g.Other project should meet under Pharmacopoeia of People's Republic of China version capsule in 2005 item.This capsule is used for the treatment of acute or chronic inflammation such as pneumonia, trachitis, phlebitis etc., has positive effect.
Embodiment 14:
Get Cynanversicoside A 9g, add propylene glycol and each 20ml of ethanol, stir and make dissolving, add injection and be diluted with water to 10000ml, cross the millipore filtration of 0.22 μ m, embedding, 10ml/ bottle, flowing steam sterilization in 30 minutes, check, packing, get the Cynanversicoside A injection liquid, be used for the treatment of acute inflammation such as acute tonsillitis, upper respiratory tract infection, acute gastroenteritis, phlebitis etc., have positive effect.
Embodiment 15:
Get Cynaversicoside D 32g, cross 100 mesh sieves; Get beeswax 4.2g, add soybean oil 125g, fusion mixing under 80 ℃ of water-baths is cooled to room temperature (25 ℃).Add butyl hydroxy anisol, Citric Acid, fully mixing.Add Cynaversicoside D, Yelkin TTS 5g adds soybean oil to 250g, and fully mixing as capsule heart liquid, is pressed into 1000 soft capsules, is used for the treatment of upper respiratory tract infection, tonsillitis, has good result.
Embodiment 16:
Precision takes by weighing the Glaucoside H 20g of recipe quantity and lactose 40g, Microcrystalline Cellulose 70g, polyvinylpolypyrrolidone (5.25g), aspartame 2.5g, polyvidone 6.0g, sodium bicarbonate 4.0g, progressively increases method with the main ingredient Glaucoside H and various auxiliary material is manual earlier mixes by equivalent.Cross twice of 80 mesh sieve.Material behind the mixing is put in the appropriate containers, and it is an amount of to add 75% ethanolic soln contain 15% (g/100ml) polyethylene glycol 6000, the system softwood.20 orders pushed the sieve series wet granular.Wet granular is divided in enamel tray, puts in the air blast thermostatic drying chamber 70 ℃ of dryings 2 hours.The weight of accurate weighing dried particles, the residue polyvinylpolypyrrolidone of adding 2.25g, the amount by 1% adds sodium lauryl sulphate (SDS), and behind the mixing, the circular punch die of 7mm is pressed into 1000.Promptly get 1000 of Glaucoside H dispersible tablets.Be used for the treatment of chronic intestinal inflammations, have good result.
Embodiment 17:
24.02g polyethylene glycol 6000,6.00g poloxamer 188 are put in the beaker, heating makes fusion in 95 ℃ of water-baths, stir, add 6.40g Cynanosides I, stir, add the 10ml anhydrous alcohol for medical use, fully stir, make Cynanosides I dissolving, continue to stir, make the ethanol volatilization, heat preservation for standby use.The preheating of DW-1 type dripping pill machine, making fluid storage compartment temperature constant temperature is 95 ± 2 ℃, refrigerant is chilled to 10～12 ℃ in advance, regulate water dropper (internal diameter is 2.5mm) and be about 11～13cm with the distance of cooling off liquid level, pour soup into fluid storage compartment, start and drip the system valve, soup is dropwise splashed in the refrigerant, regulate a speed and be about 30 droplets/minute.In collecting a mouthful collection dripping pill, absorb the surface cool agent with gauze, freezer compartment of refrigerator (18 ℃) freezing treatment 24 hours is put in the vacuum drying oven, and normal temperature vacuum-drying 24 hours promptly gets Cynanosides I dripping pill.Be used for the treatment of pneumonia, upper respiratory tract infection etc., have good result.
Claims (7)
1, a kind of scheelite total saponin(e and saponins compound, it is characterized in that from the radix cynanchi atrati medicinal material, separating and obtain, the radix cynanchi atrati saponins compound is 9 kinds of carbon-21 steroidal saponin(es, be respectively: Cynanversicoside A, Cynanversicoside B, Cynaversicoside C, Cynaversicoside D, glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, glaucoside C, Glaucoside H, Atratoglaucosides A and Cynanosides I, scheelite total saponin(e are the mixture of weight content 〉=50% that comprises carbon-21 steroidal saponin(e and saponins compound; These 9 kinds of carbon-21 steroidal saponin(es are 9 kinds of glucosides that one of them and different quantities of 3 kinds of steroid sapogenins shown in following 3 chemical structures, dissimilar sugar form, and wherein R is a sugar chain:
Glaucogenin A Glaucogenin C Glaucogenin D
2, scheelite total saponin(e according to claim 1 and saponins compound is characterized in that in described 9 kinds of carbon-21 steroidal saponin(es:
Among the Cynanchum versicolor Bunge A, aglycon is Glaucogenin C, and R is the lucky pyrans of β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl;
Among the Cynanchum versicolor Bunge B, aglycon is Glaucogenin C, and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl;
Among the Cynanchum versicolor Bunge C, aglycon is Glaucogenin D, and R is β-D-Folium seu Cortex Nerii pyrans glycosyl;
Among the Cynanchum versicolor Bunge D, aglycon is Glaucogenin D, and R is the lucky pyrans of β-D-Apocynum cannabinum pyranose-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl;
In glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, aglycon is Glaucogenin C, and R is β-D-Semen Thevetiae pyrans glycosyl;
In the glaucoside C, aglycon is Glaucogenin A, and R is the lucky pyrans of α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyrans glycosyl;
In the Glaucoside H, aglycon is Glaucogenin A, and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-α-L-Apocynum cannabinum pyrans glycosyl-(1 → 4)-β-D-enlightening glycosyl-(1 → 4)-β-L-Apocynum cannabinum pyrans glycosyl;
Among the atratoglaucosides A, aglycon is Glaucogenin C, and R is the lucky pyrans of α-L-enlightening glycosyl-(1 → 4)-β-D-Semen Thevetiae pyrans glycosyl;
Among the Cynanosides I, aglycon is Glaucogenin A, and R is the lucky pyrans of β-D-glucopyanosyl base-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl-(1 → 4)-α-L-enlightening glycosyl-(1 → 4)-β-D-Apocynum cannabinum pyrans glycosyl.
3, scheelite total saponin(e according to claim 1 and saponins compound is characterized in that described scheelite total saponin(e is the mixture that includes a kind of or its any several combinations in Cynanversicoside A, Cynanversicoside B, Cynaversicoside C, Cynaversicoside D, glaucogenin C-3-O-β-D-Semen Thevetiae glucosides, glaucoside C, Glaucoside H, these 9 kinds of carbon-21 steroidal saponin(es of atratoglaucosides A, cynanosides I.
4, as the application in preparation prevention and treatment acute or chronic inflammation and relative disease medicine according to claim 1 scheelite total saponin(e and saponins compound.
5, application according to claim 4 is characterized in that acute or chronic inflammation comprises: upper respiratory tract infection, tonsillitis, pharyngolaryngitis, gastro-enteritis, pneumonia, trachitis and phlebitis.
6, as scheelite total saponin(e according to claim 1 and saponins compound, the pharmaceutical composition of forming with pharmaceutically acceptable carrier of its prevention and treatment acute or chronic inflammation and relative disease significant quantity.
7, pharmaceutical composition according to claim 6 is characterized in that formulation has tablet, granule, capsule, oral liquid, dripping pill, mixture, syrup, tincture or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100247508A CN100443498C (en) | 2006-03-16 | 2006-03-16 | Application of total saponins and saponin compounds of Baiwei in anti-inflammatory drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100247508A CN100443498C (en) | 2006-03-16 | 2006-03-16 | Application of total saponins and saponin compounds of Baiwei in anti-inflammatory drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1817898A true CN1817898A (en) | 2006-08-16 |
| CN100443498C CN100443498C (en) | 2008-12-17 |
Family
ID=36918120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100247508A Expired - Fee Related CN100443498C (en) | 2006-03-16 | 2006-03-16 | Application of total saponins and saponin compounds of Baiwei in anti-inflammatory drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100443498C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693036B (en) * | 2009-10-21 | 2011-11-09 | 中国人民解放军第二军医大学 | Application of cynanversicoside C in preparation of medicines for treating malaria |
| CN102329358A (en) * | 2011-05-31 | 2012-01-25 | 苏州派腾生物医药科技有限公司 | Preparation method of cynatratoside A |
| CN101549000B (en) * | 2008-04-02 | 2012-07-04 | 天津天士力制药股份有限公司 | Effective component of cynanchum atratum and preparation method thereof |
| CN110946888A (en) * | 2019-12-26 | 2020-04-03 | 北京农学院 | Application of cynanchum atratum in preparation of medicine for protecting intestinal inflammation of animals |
| CN111012813A (en) * | 2019-12-26 | 2020-04-17 | 北京农学院 | Application of cynanchum atratum in preparation of medicine for protecting intestinal tract injury of animals |
| CN111358804A (en) * | 2020-04-20 | 2020-07-03 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Application of Cynanoside H in the preparation of drugs for preventing and treating breast cancer |
-
2006
- 2006-03-16 CN CNB2006100247508A patent/CN100443498C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101549000B (en) * | 2008-04-02 | 2012-07-04 | 天津天士力制药股份有限公司 | Effective component of cynanchum atratum and preparation method thereof |
| CN101693036B (en) * | 2009-10-21 | 2011-11-09 | 中国人民解放军第二军医大学 | Application of cynanversicoside C in preparation of medicines for treating malaria |
| CN102329358A (en) * | 2011-05-31 | 2012-01-25 | 苏州派腾生物医药科技有限公司 | Preparation method of cynatratoside A |
| CN110946888A (en) * | 2019-12-26 | 2020-04-03 | 北京农学院 | Application of cynanchum atratum in preparation of medicine for protecting intestinal inflammation of animals |
| CN111012813A (en) * | 2019-12-26 | 2020-04-17 | 北京农学院 | Application of cynanchum atratum in preparation of medicine for protecting intestinal tract injury of animals |
| CN111358804A (en) * | 2020-04-20 | 2020-07-03 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | Application of Cynanoside H in the preparation of drugs for preventing and treating breast cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100443498C (en) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857343A (en) | Chinese medicine composition for preventing and treating viral cold and throat disease and its preparing method | |
| CN102641326A (en) | Membranous milkvetch root extract, as well as preparation and application methods thereof | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| CN102526427B (en) | Traditional Chinese medicinal composition for treating gastrointestinal diseases and quality inspection method | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN103816300A (en) | Traditional Chinese medicine pressurized spray for treating skin disorders or mucosa orifice diseases | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN107383150B (en) | A compound with anti-hepatic damage activity and its preparation method and application | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN105535533A (en) | Traditional Chinese medicine composition for treatinggastritis | |
| CN104857043A (en) | Radix bupleuri extract and preparation method thereof | |
| CN1803179B (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN102988552A (en) | Traditional Chinese medicine compound radix pulsatillae particle for treating chicken colibacillosis and preparation method and application thereof | |
| CN102145076B (en) | The pharmaceutical applications of Radix Rehmanniae and extract thereof | |
| CN111588742A (en) | Application of myrrh sesquiterpene extract in preparation of chronic obstructive pulmonary disease medicine | |
| CN1775254A (en) | Medicinal preparation for treating deaf and preparing method | |
| CN100534476C (en) | Traditional Chinese medicine composition made by isatis root and rhizoma belamcandae, and its preparation method and use | |
| CN1814025A (en) | Detoxification and itching-relieving medicine composition and preparing method | |
| CN1762359A (en) | Alkaloid alkaloids, preparation method and application in pharmacy | |
| CN105982998B (en) | A kind of pharmaceutical composition and its preparation method and application for treating fatty liver | |
| CN103880913A (en) | Compound with liver protection effect and application thereof | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN102764314A (en) | Traditional Chinese medicine compound Lianweng dysentery-inhibiting granules for curing white scour of piglets, preparation method and application thereof | |
| CN101966251B (en) | Medicinal composition for preventing and treating bronchial asthma and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081217 Termination date: 20130316 |